ulcerative colitis

New challenges, opportunities in autoimmune disease treatment
New challenges, opportunities in autoimmune disease treatmentAllegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.
Clinical team alignment top priority for payersInvestment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Study to measure impact of MTM on outcomes for IBD patientsThe effectiveness of an inflammatory bowel disease (IBD) medication therapy management (MTM) patient fulfillment model and its impact on adherence compared to standard care will be evaluated in a new study.
FDA drug approvals-June 2014FDA actions in brief, breakthrough therapy designations, fast-track designations, first-time generic approval
FDA approves treatment for ulcerative colitis and Crohn’sFDA has approved vedolizumab (Entyvio, Takeda) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s disease.
FDA pipeline previewComplete response, priority review, breakthrough therapy designations, fast-track designations, orphan drug designations, first-time generic approval
FDA actions in brief